@article{2d007d1b15074826a0d594f030d7a78f,
title = "Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”",
keywords = "Carbazoles, Humans, Lung Neoplasms/drug therapy, Piperidines/adverse effects, Receptor Protein-Tyrosine Kinases",
author = "Groenland, {Stefanie L.} and Geel, {Dieuwertje R.} and Beijnen, {Jos H.} and Smit, {Egbert F.} and Huitema, {Alwin D.R.} and Neeltje Steeghs",
note = "Funding Information: No funding was received for this work.",
year = "2021",
month = nov,
doi = "10.1002/cpt.2372",
language = "English",
volume = "110",
pages = "1164--1164",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",
}